leve

Monitoring Patient Glucose Levels: New Advances in software make it easier

Monitoring patient glucose levels and determining the response to intervention is critical when working with diabetic clients. The benefit of doing so in improved outcomes for both type 1 and type 2 diabetes has been clearly established by clinical trials conducted in both the U.S. and the UK1. Self- monitoring by patients of glucose levels, and the data provided is especially important for p...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2Diabetes Patients Announced TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - TransitionTherapeutics Inc. ("Transition") , today announces the results fromits exploratory Phase IIa clinical trial indicating that 4-weeks ofdaily treatments with gastrin-based therapy, E1-I.N.T.(TM), showedsustained reductions in blood glucose co...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 24, 2007 – Novo Nordisk today announcedresults of a new study that further demonstrated the safety andefficacy of insulin Levemir® (insulin detemir [rDNA origin]injection). Patients with Type 2 diabetes were able to adjusttheir own dosage of Levemir® and achieve improvements i...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Novo Nordisktoday announced results of a new study that further demonstratedthe safety and efficacy of insulin Levemir(R) (insulin detemir[rDNA origin] injection). Patients with type 2 diabetes were ableto adjust their own dosage of Levemir(R) and achieve improvem...

New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jun 21, 2007 - BioSantePharmaceuticals, Inc. (AMEX:BPA) today provided comment on theWomen's Health Initiative (WHI) Coronary Artery Calcium Studypublished yesterday in The New England Journal of Medicine (NEJM).The study found that younger menopausal women (aged 50-59) whoreceived a standard dose of estrogen therapy had significantly lesscoronary artery...

NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans

BETHESDA, Md., June 11, 2007--A team of researchers at theNational Cancer Institute (NCI), part of the National Institutes ofHealth (NIH), has uncovered a set of genes that are turned on, orexpressed, at high levels only in the blood vessels that feedtumors in mice and humans. These genes, and the proteins theyencode, are important new potential targets for novel drugs thatcould selectiv...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interactionwith paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration ofpaliperidone extended-release (ER) tablets, blood levels of thedrug were not affected when given with a common antidepressant,according to new data presented today at the 160th Annual Meetingof the American Psychiatric Association. Paroxetine,...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that new data showimprovements in symptoms of decreased libido, energy levels anderectile function in 76 percent of hypogonadal men after switchingbrands of testosterone replacement gel therapy. Total testosteronelevels increased significantly in patients who switched toAuxilium's Testim(R)...

Mircera Effective in Stabilising Haemoglobin Levels in Elderly Patients With Kidney Disease on Dialysis

Findings Illustrate Role of Innovative New Treatment in PopulationMost Affected by Chronic Kidney Disease BASEL, Switzerland, April 23, 2007 /PRNewswire/ -- A new RochePhase III analysis shows once-monthly MIRCERA, a continuouserythropoietin receptor activator, effectively treats renal anaemiain one of the fastest growing groups of patients with chronickidney disease (CKD) -- elderly pati...

Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen(HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week48 of Re-Treatment PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced data from a cohort ofnucleoside-naive HBeAg-negative chronic hepatitis B patients(ETV-027/901, n=99). These data showed that patients whoexperi...

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study

Chief Scientist to Present Results at 2007 American Association forCancer Research Annual Meeting CLEVELAND, April 09, 2007 /PRNewswire-FirstCall/ -- ClevelandBioLabs, Inc. , announced today the results of its study ofProtectan CBLB502's efficacy as a mitigator of bothgastrointestinal (GI) and hematopoietic (bone marrow/bloodproduction) radiation-induced damage in non-human primates. The...

New Data Confirm That Use of Levemir Can Limit Weight Gain

COPENHAGEN, April 3, 2007-Newly published results in theInternational Journal of Clinical Practice(1) from the large-scale,observational ‘PREDICTIVE™ study’*, confirm thatLevemir® for the majority of people effectively treats diabeteswithout causing weight gain.(1) The PREDICTIVE™ study is examining patient outcomes whenLevemir® – a long-acting...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

* ISIS 301012 coadministered with statins for only five weeks at400 mg/week lowered LDL-C 47% beyond the levels achieved withstatins alone, with similarly favorable effects on otheratherogenic lipids NEW ORLEANS and CARLSBAD, Calif., March 26, 2007/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced newresults from its Phase 2 clinical trial of ISIS 301012coadministered with st...

Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinicresearchers today report that the drug torcetrapib, despite raisinghigh density lipoprotein cholesterol (HDL) or the "good"cholesterol by more than 60%, did not slow the progression ofplaque buildup in the coronary arteries as measured using anultrasound probe. Steven Nissen, M.D., Chairman of Cardiovascular Medicine atCl...